ZA200301210B - Oral solid dose vaccine. - Google Patents

Oral solid dose vaccine. Download PDF

Info

Publication number
ZA200301210B
ZA200301210B ZA200301210A ZA200301210A ZA200301210B ZA 200301210 B ZA200301210 B ZA 200301210B ZA 200301210 A ZA200301210 A ZA 200301210A ZA 200301210 A ZA200301210 A ZA 200301210A ZA 200301210 B ZA200301210 B ZA 200301210B
Authority
ZA
South Africa
Prior art keywords
vaccine composition
solid dose
oral solid
dose vaccine
antigen
Prior art date
Application number
ZA200301210A
Other languages
English (en)
Inventor
Vincent Vande-Velde
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of ZA200301210B publication Critical patent/ZA200301210B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
ZA200301210A 2000-08-15 2003-02-13 Oral solid dose vaccine. ZA200301210B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0020089.9A GB0020089D0 (en) 2000-08-15 2000-08-15 Vaccine Composition

Publications (1)

Publication Number Publication Date
ZA200301210B true ZA200301210B (en) 2004-03-12

Family

ID=9897656

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200301210A ZA200301210B (en) 2000-08-15 2003-02-13 Oral solid dose vaccine.

Country Status (17)

Country Link
US (1) US20040013695A1 (no)
EP (1) EP1309344A1 (no)
JP (1) JP2004506020A (no)
KR (1) KR20030031978A (no)
CN (1) CN1842345A (no)
AU (2) AU8616801A (no)
BR (1) BR0113301A (no)
CA (1) CA2424160A1 (no)
GB (1) GB0020089D0 (no)
HU (1) HUP0301697A3 (no)
IL (1) IL154404A0 (no)
MX (1) MXPA03001392A (no)
NO (1) NO20030713L (no)
NZ (1) NZ524164A (no)
PL (1) PL362481A1 (no)
WO (1) WO2002013858A1 (no)
ZA (1) ZA200301210B (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
US20050118137A1 (en) * 2000-07-19 2005-06-02 Chih-Ping Liu Method of treatment using interferon-tau
US20050118138A1 (en) * 2000-07-19 2005-06-02 Chih-Ping Liu Method of treatment using interferon-tau
US20040247565A1 (en) * 2000-07-19 2004-12-09 Chih-Ping Liu Method of treatment using interferon-tau
US20050084478A1 (en) * 2000-10-17 2005-04-21 Chih-Ping Liu Combination therapy using interferon-tau
US20050226845A1 (en) * 2004-03-10 2005-10-13 Chih-Ping Liu Method of treatment using interferon-tau
US7431920B2 (en) * 2000-07-19 2008-10-07 Pepgen Corporation Method of treating IL-10 deficiency
US20050201981A1 (en) * 2004-03-10 2005-09-15 Chih-Ping Liu Method of optimizing treatment with interferon-tau
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US20020051794A1 (en) 2000-08-09 2002-05-02 Alk-Abello A/S Novel parenteral vaccine formulations and uses thereof
ATE361097T1 (de) * 2002-01-15 2007-05-15 Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh Orale vakzinierung mit dem tumor-antigen-mimotop gln-met-trp-ala-pro-gln-trp-gly-pro-asp
DE10224086A1 (de) 2002-05-31 2003-12-11 Bayer Ag Pharmazeutische Zubereitungen zur oralen Anwendung enthaltend wirkstoffbeladene Ionentauscherharze sowie strukturviskose Gelbildner als Verdicker
AU2003280324A1 (en) 2002-11-26 2004-06-18 Alk-Abello A/S Pharmaceutical allergen product
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
MXPA05009079A (es) 2003-02-28 2006-05-19 Alk Abello As Forma de dosificacion que tiene una matriz de sacarido.
US9050352B2 (en) 2003-10-16 2015-06-09 Stephen John Ralph Immunomodulating compositions and uses therefor
US20060078942A1 (en) * 2004-03-10 2006-04-13 Pepgen Corporation Method of treatment using interferon-tau
US20080025948A1 (en) * 2004-03-10 2008-01-31 Chih-Ping Liu Methods of Treatment Using Interferon-Tau
US20060115499A1 (en) * 2004-09-27 2006-06-01 Alk-Abello A/S Liquid allergy vaccine formulation for oromucosal administration
KR20080059289A (ko) 2005-10-04 2008-06-26 알크-아벨로 에이/에스 고체 백신 제형
EP1854478A1 (en) * 2006-05-12 2007-11-14 Cytos Biotechnology AG Nicotine-carrier vaccine formulation
US20110111023A1 (en) 2007-09-11 2011-05-12 Kobenhavns Universitet Prevention of type 1 diabetes by administration of gliadin
GB201009273D0 (en) * 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
FR2960781B1 (fr) * 2010-06-07 2013-11-22 Sanofi Pasteur Preparation d'un vaccin oral sec stabilise, compose d'un virus vivant attenue
MX347101B (es) * 2010-10-08 2017-04-12 Scherer Technologies Llc R P Forma de dosis de disolucion rapida de vacuna oral que usa almidon.
AU2011336410B2 (en) 2010-12-02 2015-01-22 Oncolytics Biotech Inc. Lyophilized viral formulations
WO2012075379A2 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Liquid viral formulations
WO2012103472A1 (en) * 2011-01-28 2012-08-02 Brian Pulliam Granularized particular thermostable rotovirus vaccine preparation
AU2013228096B2 (en) * 2012-03-05 2017-07-13 Intravacc B.V. Methods and compositions for stabilizing dried biological materials
WO2015013549A1 (en) * 2013-07-25 2015-01-29 Invado Pharmaceuticals, LLC Treating oral inflammation, injury or pain
US11801223B2 (en) * 2013-12-31 2023-10-31 Access To Advanced Health Institute Single vial vaccine formulations
EP2952200A1 (en) 2014-06-04 2015-12-09 Alk-Abelló A/S Allergen for prophylactic treatment of allergy
WO2017090766A1 (ja) * 2015-11-27 2017-06-01 日東電工株式会社 口腔内投与用ワクチン医薬組成物及び口腔内投与用ワクチン医薬組成物の製造方法
EP3381468A4 (en) * 2015-11-27 2019-06-05 Nitto Denko Corporation DRIED INFLUENZA VACCINE PREPARATION AND METHOD FOR PRODUCING A DRIED INFLUENZED VACCINE PREPARATION

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) * 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4636385A (en) * 1985-02-15 1987-01-13 The Wistar Institute Of Anatomy & Biology Vaccine, method for its preparation, and use thereof in vaccinating humans against rotavirus infection
GB9722682D0 (en) * 1997-10-27 1997-12-24 Scherer Ltd R P Pharmaceutical products
DE122006000026I1 (de) * 1999-08-17 2006-10-12 Glaxosmithkline Biolog Sa Methoden um Rotavirusvarianten zu trennen und lebender attenuierter Rotavirus impfstoff
KR100366608B1 (ko) * 2000-02-15 2003-01-09 마스터진(주) 형질전환 식물체로부터 생산된 재조합 인간 파필로마바이러스 백신

Also Published As

Publication number Publication date
CA2424160A1 (en) 2002-02-21
HUP0301697A2 (hu) 2003-08-28
IL154404A0 (en) 2003-09-17
NZ524164A (en) 2004-10-29
AU8616801A (en) 2002-02-25
CN1842345A (zh) 2006-10-04
US20040013695A1 (en) 2004-01-22
NO20030713L (no) 2003-04-11
EP1309344A1 (en) 2003-05-14
WO2002013858A1 (en) 2002-02-21
BR0113301A (pt) 2003-07-15
JP2004506020A (ja) 2004-02-26
AU2001286168B2 (en) 2004-09-23
HUP0301697A3 (en) 2004-11-29
MXPA03001392A (es) 2004-12-13
NO20030713D0 (no) 2003-02-14
PL362481A1 (en) 2004-11-02
KR20030031978A (ko) 2003-04-23
GB0020089D0 (en) 2000-10-04

Similar Documents

Publication Publication Date Title
ZA200301210B (en) Oral solid dose vaccine.
AU2001286168A1 (en) Oral solid dose vaccine
AU746163B2 (en) Adjuvant compositions
AU765824B2 (en) Vaccines
US6506386B1 (en) Vaccine comprising an iscom consisting of sterol and saponin which is free of additional detergent
US6558670B1 (en) Vaccine adjuvants
AU728759B2 (en) Oil in water vaccine compositions
CA2383110A1 (en) Adjuvant comprising a polyoxyethylene alkyl ether or ester and at least one non-ionic surfactant
EP1528914B1 (en) Antigenic compositions
US20080095854A1 (en) Dna dosage forms
ZA200202270B (en) Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines.
MXPA00009887A (en) Adjuvant compositions
CZ20003732A3 (cs) Pomocný prostředek